ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

KIT

KIT proto-oncogene, receptor tyrosine kinase · also CD117, SCFR, C-Kit, PBT · CD molecules

15 programs in company-led studies act on KIT, from 13 companies: 8 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (12 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
regorafenibruleBayerinhibitorphase 4404 runningABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
imatinibruleNovartisinhibitorphase 4703 runningABL1, BCR, PDGFRBChEMBL
AvapritinibruleSanofiinhibitorphase 4102 runningPDGFRANCIt
velzatinibGlaxoSmithKlineinhibitorphase 388 running–the company's pipeline
anlotinibruleSino Biopharmaceuticalinhibitorphase 3407 runningFLT4, KDR, PDGFRBChEMBL
quizartinibruleDaiichi Sankyoinhibitorphase 3225 runningCSF1R, FLT3, PDGFRA, PDGFRB, RETChEMBL
masitinibruleAB Scienceinhibitorphase 3384 runningFGFR3, PDGFRA, PDGFRBChEMBL
ripretinibruleOno Pharmaceuticalinhibitorphase 393 runningPDGFRANCIt
seralutinibruleGB002, Inc., a wholly owned subsidiary of Gossamer Bioinhibitorphase 382 runningCSF1R, PDGFRA, PDGFRBChEMBL
elenestinibSanofiinhibitorphase 331 running–the company's pipeline
NB-003ruleNingbo Newbay Technology Developmentinhibitorphase 321 running–NCIt
BLU-808Sanofiinhibitorphase 231 running–the company's pipeline
THB335ruleCalixisinhibitorphase 221 running–the studies' text
briquilimabruleJasper Therapeutics–phase 270 running–NCIt
Anti-c-Kit/MMAE Antibody-Drug Conjugate NN3201ruleNovelty Nobility–phase 111 running–NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.